Each week, AIM staff compile new or moving legislation in jurisdictions all over the country.
This legislative summary is for the week of April 22, 2022.
Please Note: AIM is striving to monitor fast-moving state legislative developments. The information included in this summary may not be comprehensive and is subject to change. Please consult the linked jurisdiction websites for the most up-to-date information on each bill. If you are aware of missing information, please notify us. For individualized support, contact AIM Chief Policy and Government Relations Officer Brent Ewig. AIM would like to thank ASTHO for the ongoing partnership and support that makes these summaries possible and invite you to check out AIM’s Policy Toolkit for more legislative resources.
Movement on Existing Bills
COVID-19: School Requirements, Mandates and Exemptions
- LA HB 990 passed the House and moved to the Senate on 4/21/22. This bill would prohibit state and local agencies from imposing a COVID-19 vaccine requirement as a condition of entry for public or private spaces. This bill would also nullify existing Louisiana regulation to have the COVID-19 vaccine required for K-12 schools, scheduled to go into effect for the 22-23 academic year. Lastly, this bill would expressly allow private businesses and private entities to require COVID-19 vaccination for entry.
- MO HB 2331 – moved to the Senate on 4/14/22. This bill would prohibit consideration of COVID-19 vaccination status of organ transplant recipients or donors.
- NH SB 288 passed the Senate and moved to the House and is scheduled for a public hearing on 4/19/22. This bill would establish a committee to examine health department policies related to immunizations for children. The committee shall report findings on or before Dec 1, 2022.
- TN HB 1871 was sent to the Governor on 4/19/22. This bill would prohibit governmental entities, local education agencies, schools, and private businesses from adopting or enforcing laws, rules, or practices that fail to recognize natural immunity as providing a level of immune protection that is at least as protective as a COVID-19 vaccine or treat individuals with natural immunity differently than individuals who have received the COVID-19 vaccine.